应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
AUPH Aurinia Pharmaceuticals Inc
盘前交易 05-13 06:35:47 EDT
5.02
-0.15
-2.90%
最高
5.19
最低
5.02
成交量
118.88万
今开
5.15
昨收
5.17
日振幅
3.37%
总市值
7.16亿
流通市值
6.52亿
总股本
1.43亿
成交额
602.07万
换手率
0.92%
流通股本
1.30亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
暂无数据
公司概况
公司名称:
Aurinia Pharmaceuticals Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
Aurinia Pharmaceuticals Inc.是根据《商业公司法》组建的(加拿大阿尔伯塔省)。Aurinia制药是一家完全整合的生物制药公司,专注于提供治疗目标患者群体的疗法,这些患者群体受到自身免疫、肾脏和罕见病的影响,医疗需求未得到满足。2021年1月,Aurinia制药推出了首个获得FDA批准的口服药物LUPKYNIS(voclosporin),用于治疗活动性LN成人患者。LUPKYNIS是一种口服CNI免疫抑制剂,当与霉酚酸酯(MMF)(尽管MMF目前尚未被批准)和类固醇联合使用时,已被证明可以改善LN的近期和长期结果。通过抑制钙调神经磷酸酶,LUPKYNIS降低细胞因子活化,阻断白细胞介素IL-2表达和T细胞介导的免疫反应。LUPKYNIS还可能稳定足细胞,从而防止蛋白尿。
发行价格:
--
{"stockData":{"symbol":"AUPH","market":"US","secType":"STK","nameCN":"Aurinia Pharmaceuticals Inc","latestPrice":5.02,"timestamp":1715371200000,"preClose":5.17,"halted":0,"volume":1188762,"delay":0,"floatShares":129800797,"shares":142663526,"eps":-0.435739,"marketStatus":"盘前交易","marketStatusCode":1,"change":-0.15,"latestTime":"05-13 06:35:47 EDT","open":5.15,"high":5.194,"low":5.02,"amount":6020661.7990332,"amplitude":0.033656,"askPrice":6.05,"askSize":100,"bidPrice":5.02,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.435739,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1715607000000},"adr":0,"listingDate":951454800000,"adjPreClose":5.02,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":5.02,"preClose":5.02,"latestTime":"19:59 EDT","volume":37388,"amount":187702.5728,"timestamp":1715385561407},"volumeRatio":1.0300696380608607},"requestUrl":"/m/hq/s/AUPH/tweets","defaultTab":"tweets","newsList":[],"profile":{"websiteUrl":"http://www.auriniapharma.com","stockEarnings":[{"period":"1week","weight":-0.0157},{"period":"1month","weight":0.006},{"period":"3month","weight":-0.3945},{"period":"6month","weight":-0.3514},{"period":"1year","weight":-0.5428},{"period":"ytd","weight":-0.4416}],"compareEarnings":[{"period":"1week","weight":0.0187},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0392},{"period":"6month","weight":0.1821},{"period":"1year","weight":0.2638},{"period":"ytd","weight":0.0958}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aurinia Pharmaceuticals Inc.是根据《商业公司法》组建的(加拿大阿尔伯塔省)。Aurinia制药是一家完全整合的生物制药公司,专注于提供治疗目标患者群体的疗法,这些患者群体受到自身免疫、肾脏和罕见病的影响,医疗需求未得到满足。2021年1月,Aurinia制药推出了首个获得FDA批准的口服药物LUPKYNIS(voclosporin),用于治疗活动性LN成人患者。LUPKYNIS是一种口服CNI免疫抑制剂,当与霉酚酸酯(MMF)(尽管MMF目前尚未被批准)和类固醇联合使用时,已被证明可以改善LN的近期和长期结果。通过抑制钙调神经磷酸酶,LUPKYNIS降低细胞因子活化,阻断白细胞介素IL-2表达和T细胞介导的免疫反应。LUPKYNIS还可能稳定足细胞,从而防止蛋白尿。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.106403},{"month":2,"riseRate":0.5,"avgChangeRate":0.009372},{"month":3,"riseRate":0.4,"avgChangeRate":0.102117},{"month":4,"riseRate":0.6,"avgChangeRate":-0.012088},{"month":5,"riseRate":0.5,"avgChangeRate":-0.011952},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.039513},{"month":7,"riseRate":0.555556,"avgChangeRate":0.03731},{"month":8,"riseRate":0.444444,"avgChangeRate":-0.068337},{"month":9,"riseRate":0.444444,"avgChangeRate":0.078247},{"month":10,"riseRate":0.6,"avgChangeRate":0.041208},{"month":11,"riseRate":0.5,"avgChangeRate":-0.001599},{"month":12,"riseRate":0.4,"avgChangeRate":0.111111}],"exchange":"NASDAQ","name":"Aurinia Pharmaceuticals Inc","nameEN":"Aurinia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aurinia Pharmaceuticals Inc(AUPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Aurinia Pharmaceuticals Inc(AUPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Aurinia Pharmaceuticals Inc,AUPH,Aurinia Pharmaceuticals Inc股票,Aurinia Pharmaceuticals Inc股票老虎,Aurinia Pharmaceuticals Inc股票老虎国际,Aurinia Pharmaceuticals Inc行情,Aurinia Pharmaceuticals Inc股票行情,Aurinia Pharmaceuticals Inc股价,Aurinia Pharmaceuticals Inc股市,Aurinia Pharmaceuticals Inc股票价格,Aurinia Pharmaceuticals Inc股票交易,Aurinia Pharmaceuticals Inc股票购买,Aurinia Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aurinia Pharmaceuticals Inc(AUPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Aurinia Pharmaceuticals Inc(AUPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}